Kalaris Therapeutics (NASDAQ:KLRS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) to a hold rating in a report released on Friday morning.

Other equities analysts have also recently issued reports about the company. Raymond James Financial assumed coverage on Kalaris Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating for the company. Piper Sandler set a $3.00 target price on Kalaris Therapeutics and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Finally, Weiss Ratings restated a “sell (e)” rating on shares of Kalaris Therapeutics in a research report on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kalaris Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Kalaris Therapeutics Stock Down 6.3%

Shares of KLRS opened at $6.64 on Friday. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $24.15. The stock has a 50 day moving average of $3.79.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Institutional Investors Weigh In On Kalaris Therapeutics

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 24,234 shares of the company’s stock, valued at approximately $65,000. XTX Topco Ltd owned about 0.13% of Kalaris Therapeutics at the end of the most recent reporting period. 66.05% of the stock is owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.